Our previous controlled, open‐label randomized trial has indicated that a low dose of IL‐2 administration at Day 60 reduced the incidence of chronic GVHD (cGVHD) and translated into improved GVHD progression‐free survival (GPFS) post allo‐HSCT [13]. Here, IL2 is linked to graft versus host disease.